Madrigal Pharmaceuticals revenue and financials

MDGL · NASDAQ · USD

Compare Madrigal Pharmaceuticals
$421.99Change from previous close: −0.46%Absolute change: −$1.97

Close · November 17, 2026

In the fiscal year ended December 2025, Madrigal Pharmaceuticals reported revenue of $958.4M (+432.05% year over year). The net loss was $288.28M.

Annual revenue · 2025: $958.4M
  1. $180.13M2024
  2. $958.4M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+432.05%
2025 vs 2024
Net margin
-30.1%
2024: -258.6%

How Madrigal Pharmaceuticals is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue9581800.00.00.00.00.00.00.0—
Cost of revenue56.16.20.00.0——————
Gross profit9021740.00.0——————
Selling, general and administrative81443510848.137.321.922.615.37.76.6
Research and development38923727224520518572.325.424.415.9
Operating income-300-498-380-294-242-207-95.0-40.7-32.1-25.2
EBIT-300-498-380-294-242-207-95.0-40.7-32.1-22.5
EBITDA-299-497-380-293-242-206-94.9-40.6-32.0-22.5
Interest expense22.314.712.74.00.00.0———1.2
Pre-tax income-288-466-374-295-242-202-83.9-32.8-31.2-26.4
Income tax0.00.00.00.00.00.00.00.0——
Net income-288-466-374-295-242-202-83.9-32.8-31.2-26.4
Net income to common shareholders-288-466-374-295-242-202-83.9-32.8-31.2-26.4
Basic EPS-12.85-21.90-19.99-17.23-14.63-13.09-5.45-2.22-2.54-5.07
Diluted EPS-12.85-21.90-19.99-17.23-14.63-13.09-5.45-2.22-2.54-5.07
Average shares (basic)22.421.318.717.116.515.415.414.812.25.2
Average shares (diluted)22.421.318.717.116.515.415.414.812.25.2

Companies in the group: same industry, similar size